Advances in Nanotechnology in the Diagnosis and Treatment of Gynecological Cancers
Abstract
Nanotechnology platforms facilitate therapeutic drug delivery and offer various advantages over conventional drugs, such as biocompatibility, non-inflammatory effects, high therapeutic output, biodegradability, non-toxicity, and biocompatibility. Due to the inherent drawbacks of conventional drug delivery to cancerous tissues, nanotechnology-based alternatives have been developed for such diseases. Gynecologic malignant tumors (GCs), include various types of cervical, endometrial, and ovarian cancers. The epidemiological characteristics of the tumors show that their incidence is increasing significantly and tends to be younger, which is a serious threat to women's physical and mental health. This article provides a systematic review of the latest research results on nanomaterials in the diagnosis and treatment of gynecological malignancies, including 2 sections on nanomaterials-based diagnostic and therapeutic strategies in gynecological cancers. In particular, the article also analyzes the challenges faced by nanotechnology, including toxicity, technology, and clinical translation issues. These applications not only improve the therapeutic efficacy of gynecological cancers, but also reduce the toxicity and side effects, and provide a new direction for the precise treatment of gynecological cancers.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Chaos and quantum thermalization
- The Dalton quantum chemistry program system
- Cord Blood Leptin and Adiponectin as Predictors of Adiposity in Children at 3 Years of Age: A Prospective Cohort Study
- Quantitative metabolomics by H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes
- Stable adiabatic quantum batteries
- A novel self-lipid antigen targets human T cells against CD1c(+) leukemias
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.